Loading...
OTCM
BIEL
Market cap7mUSD
Oct 07, Last price  
0.00USD
1D
-10.94%
1Q
-5.00%
Jan 2017
-18.57%
IPO
-99.96%
Name

BioElectronics Corp

Chart & performance

D1W1MN
OTCM:BIEL chart
P/E
—
P/S
13.79
EPS
—
Div yield, %
—
Shrs. gr., 5y
0.98%
Rev. gr., 5y
-9.25%
Revenues
511k
+2.94%
665,5101,289,8962,339,6462,089,6941,763,7651,045,873941,761829,5631,609,460707,412714,708496,032510,623
Net income
-532k
L-42.78%
-2,445,620-2,677,329-2,450,249-2,106,723-2,118,793-2,988,344-2,325,279-1,159,722-289,821-784,910-722,812-930,650-532,487
CFO
-151k
L-7.76%
00-1,719,709-1,307,641-868,908-1,352,414-715,683-528,037-320,299-478,601-335,991-164,153-151,412

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

BioElectronics Corporation, an electroceutical company, engages in the development and sale of wearable, neuromodulation devices to mitigate neurological diseases and enhance quality of life worldwide. Its products include ActiPatch, a musculoskeletal pain therapy; Allay, a menstrual pain therapy; and Smart Insole, a heel pain therapy. The company also offers RecoveryRx, a medical device that provides pain management therapy for medical professionals; and HealFast, a drug-free therapy for horses, cats, and dogs that reduces swelling and pain, as well as heals muscle and tendon injuries, sores, and incisions. It sells its products to wholesale distributors, hospitals and clinics, and consumers. The company was incorporated in 2000 and is headquartered in Frederick, Maryland.

Key people

John Martinez
Vice President - Engineering · since 2019
William Monn
Vice President - Production · since 2013
Keith Nalepka
Vice President - Sales, Director · since 2019
Ben Fichter
Marketing Manager · since 2010
Ian Rawe
Director - Clinical Research
Sree Koneru
Director · since 2024
Richard Staelin
Chairman of the Board · since 2020
Kelly Whelan
President, Chief Executive Officer, Treasurer, Director · since 2019
IPO date
Apr 12, 2004
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT